Hester van Cruijsen
Overview
Explore the profile of Hester van Cruijsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smit K, Derksen J, Beets G, Belt E, Berbee M, Coene P, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205748
Regular physical activity (PA) is associated with improved overall survival (OS) in stage I-III colorectal cancer (CRC) patients. This association is less defined in patients with metastatic CRC (mCRC). We...
2.
van der Linden N, Kok A, Leermakers-Vermeer M, de Roos N, de Bree R, van Cruijsen H, et al.
Nutr Clin Pract
. 2017 Apr;
32(2):225-232.
PMID: 28362572
Background: Chemoradiotherapy (CRT) is a major risk factor for malnutrition and dehydration in patients with head and neck cancer. Enteral support is often needed, and a percutaneous endoscopic gastrostomy (PEG)...
3.
Oosterhoff D, Lougheed S, van de Ven R, Lindenberg J, van Cruijsen H, Hiddingh L, et al.
Oncoimmunology
. 2012 Aug;
1(5):649-658.
PMID: 22934257
Targeting dendritic cells (DC) through the release of suppressive factors is an effective means for tumors to escape immune control. We assessed the involvement of downstream signaling through the JAK2/STAT3...
4.
van Cruijsen H, Oosterhoff D, Lindenberg J, Lougheed S, Fehres C, Weijers K, et al.
Immunotherapy
. 2011 Sep;
3(9):1051-61.
PMID: 21913828
Aims: Langerhans cell (LC) infiltration has been observed in glioblastoma, but the glioblastoma microenvironment may be conditioned to resist antitumor immune responses. As little is known about how glioblastoma may...
5.
Lindenberg J, Fehres C, van Cruijsen H, Oosterhoff D, de Gruijl T
Immunotherapy
. 2010 Dec;
3(1):77-96.
PMID: 21174559
Myeloid differentiation is often disturbed in cancer, leading to reduced frequencies of immunostimulatory dendritic cells and an over-representation of immunosuppressive immature myeloid cells, granulocytes and macrophages. As a result of...
6.
van Cruijsen H, Voest E, Punt C, Hoekman K, Witteveen P, Meijerink M, et al.
Eur J Cancer
. 2010 Jan;
46(5):901-11.
PMID: 20061136
Aim: Cediranib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) signalling. Preclinical and clinical data suggest that inhibition of the VEGFR and epidermal growth factor receptor...
7.
van Cruijsen H, Ruiz M, van der Valk P, de Gruijl T, Giaccone G
BMC Cancer
. 2009 Jun;
9:180.
PMID: 19519895
Background: Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are...
8.
van Cruijsen H, van der Veldt A, Hoekman K
Front Biosci (Landmark Ed)
. 2009 Mar;
14(6):2248-68.
PMID: 19273199
The number of VEGFR tyrosine kinase inhibitors (TKIs) used as an anti-cancer agent is rapidly increasing, but several issues in clinical practice remain to be elucidated. VEGFR TKIs are multikinase...
9.
Vroling L, van der Veldt A, de Haas R, Haanen J, Schuurhuis G, Kuik D, et al.
Angiogenesis
. 2009 Feb;
12(1):69-79.
PMID: 19212818
Mature circulating endothelial cell (CEC) as well as endothelial progenitor populations may reflect the activity of anti-angiogenic agents on tumor neovasculature or even constitute a target for anti-angiogenic therapy. We...
10.
van Cruijsen H, van der Veldt A, Vroling L, Oosterhoff D, Broxterman H, Scheper R, et al.
Clin Cancer Res
. 2008 Sep;
14(18):5884-92.
PMID: 18794101
Purpose: A disturbed myeloid lineage development with abnormally abundant neutrophils and impaired dendritic cell (DC) differentiation may contribute to tumor immune escape. We investigated the effect of sunitinib, a tyrosine...